Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC37011PROTAC MDM2 Degrader-2CAS: 2249944-99-6纯度: >98.50%
PROTAC MDM2 Degrader-2 是一种 PROTAC 类的 MDM2 降解剂。PROTAC MDM2 Degrader-2 由 MDM2 抑制剂,linker 和 E3 泛素连接酶 MDM2 配体组成。
- GC37012PROTAC MDM2 Degrader-3CAS: 2249750-23-8纯度: >98.50%
PROTAC MDM2 Degrader-3 是一种 PROTAC 类的 MDM2 降解剂。PROTAC MDM2 Degrader-3 由 MDM2 抑制剂,linker 和 E3 泛素连接酶 MDM2 配体组成。
- GC37013PROTAC MDM2 Degrader-4CAS: 2249750-24-9
PROTAC MDM2 Degrader-4 是一种 PROTAC 类的 MDM2 降解剂。PROTAC MDM2 Degrader-4 由 MDM2 抑制剂,linker 和 E3 泛素连接酶 MDM2 配体组成。
- GC37038Puerarin 6''-O-XylosideCAS: 114240-18-5
Puerarin 6''-O-Xyloside,是从葛根中分离得到的,拥有抗炎和抗癌活性。Puerarin 6''-O-Xyloside 可诱导线粒体介导的细胞凋亡通路。
- GC37524RGD peptide (GRGDNP) TFACAS: 114681-65-1纯度: >98.00%
An inhibitor of integrin- ligand interactions
- GC37533RIP1 kinase inhibitor 1CAS: 2095515-38-9纯度: >99.50%
RIP1 kinase inhibitor 1 (compound 22) 是一种高效的,口服有效的,可穿透大脑的 RIP1 激酶抑制剂 (pKi=9.04)。
- GC37536RIPK1-IN-7CAS: 2300982-44-7纯度: >98.50%
RIPK1-IN-7 is a potent and selective receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM.
- GC37664Sorafenib (D3)CAS: 1130115-44-4纯度: >99.00%
An internal standard for the quantification of sorafenib
- GC37665Sorafenib (D4)CAS: 1207560-07-3
Sorafenib D4 (Bay 43-9006 D4) 是 Sorafenib 氘代化合物标准品。Sorafenib 是一种多激酶抑制剂,抑制 Raf-1,B-Raf 和 VEGFR-3 的 IC50 分别为6 nM,20 nM,22 nM。
- GC37668Soyasapogenol ACAS: 508-01-0纯度: >99.00%
Soyasapogenol A是一种从Abrus cantoniensis根中分离得到的三萜类化合物,具有抗炎、抗癌、保肝和抗HIV-1等活性。
- GC37688STAT3-IN-1CAS: 2059952-75-7纯度: >98.00%
STAT3-IN-1是一种强效、选择性且口服有效的STAT3抑制剂,在HT29和MDA-MB-231细胞中的IC 50 值分别为1.82μM和2.14μM。
- GC37715Taccalonolide ACAS: 108885-68-3
Taccalonolide A 是一种微管稳定剂,是从 Tacca chantrieri 中分离得到的类固醇,具有细胞毒性和抗疟活性。Taccalonolide A 能引起 G2-M 期滞留、Bcl-2 磷酸化,并引发细胞凋亡。Taccalonolide A 在体外对过表达 p 糖蛋白 (Pgp)、多药耐药蛋白 7 (MRP7) 的细胞系具有显著的抑制作用,抑制SK-OV-3细胞生长的 IC50 值为 622 nM。
- GC37745Taurodeoxycholic acid sodium hydrateCAS: 110026-03-4纯度: >98.00%
Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. It activates S1PR2 pathway in addition to the TGR5 pathway.
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC37011 | PROTAC MDM2 Degrader-2 | 2249944-99-6 | >98.50% | |
PROTAC MDM2 Degrader-2 是一种 PROTAC 类的 MDM2 降解剂。PROTAC MDM2 Degrader-2 由 MDM2 抑制剂,linker 和 E3 泛素连接酶 MDM2 配体组成。 | ||||
| GC37012 | PROTAC MDM2 Degrader-3 | 2249750-23-8 | >98.50% | |
PROTAC MDM2 Degrader-3 是一种 PROTAC 类的 MDM2 降解剂。PROTAC MDM2 Degrader-3 由 MDM2 抑制剂,linker 和 E3 泛素连接酶 MDM2 配体组成。 | ||||
| GC37013 | PROTAC MDM2 Degrader-4 | 2249750-24-9 | - | |
PROTAC MDM2 Degrader-4 是一种 PROTAC 类的 MDM2 降解剂。PROTAC MDM2 Degrader-4 由 MDM2 抑制剂,linker 和 E3 泛素连接酶 MDM2 配体组成。 | ||||
| GC37035 | PTC-028 | 1782970-28-8 | >98.00% | |
A BMI1 inhibitor | ||||
| GC37038 | Puerarin 6''-O-Xyloside | 114240-18-5 | - | |
Puerarin 6''-O-Xyloside,是从葛根中分离得到的,拥有抗炎和抗癌活性。Puerarin 6''-O-Xyloside 可诱导线粒体介导的细胞凋亡通路。 | ||||
| GC37524 | RGD peptide (GRGDNP) TFA | 114681-65-1 | >98.00% | |
An inhibitor of integrin- ligand interactions | ||||
| GC37533 | RIP1 kinase inhibitor 1 | 2095515-38-9 | >99.50% | |
RIP1 kinase inhibitor 1 (compound 22) 是一种高效的,口服有效的,可穿透大脑的 RIP1 激酶抑制剂 (pKi=9.04)。 | ||||
| GC37535 | RIPK1-IN-3 | 2242677-36-5 | - | |
RIPK1-IN-3 (Example 38) 是RIPK1 的抑制剂,信息来自专利WO2018148626A1,拥有抗炎活性。 | ||||
| GC37536 | RIPK1-IN-7 | 2300982-44-7 | >98.50% | |
RIPK1-IN-7 is a potent and selective receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor with a Kd of 4 nM and an enzymatic IC50 of 11 nM. | ||||
| GC37537 | RIPK-IN-4 | 2141969-56-2 | >99.00% | |
RIPK-IN-4 是一种有效选择性的、具有良好的口服生物利用度的 RIPK2 抑制剂,IC50 值为 3 nM。 | ||||
| GC37538 | Ripretinib | 1442472-39-0 | >98.00% | |
A KIT and PDGFRα inhibitor | ||||
| GC37549 | RO-5963 | 1416663-77-8 | - | |
RO-5963 是 p53-MDM2 和 p53-MDMX 互相作用的双抑制剂,IC50 值分别约为 17 nM 和 24 nM。 | ||||
| GC37555 | Roquinimex | 84088-42-6 | >98.50% | |
An immunomodulator with diverse biological activities | ||||
| GC37633 | SF1126 | 936487-67-1 | - | |
SF1126 是临床相关的双重 PI3K/BRD4 泛抑制剂,具有抗肿瘤和抗血管生成活性。SF1126 是 RGDS-缀合的 LY294002 前药,其设计为表现出增加的溶解度并与肿瘤区室内的特定整联蛋白结合。SF1126 诱导细胞凋亡 (apoptosis)。 | ||||
| GC37646 | SKF-86002 | 72873-74-6 | >99.00% | |
An anti-inflammatory agent | ||||
| GC37649 | SM-164 Hydrochloride | - | >99.00% | |
A cell-permeable Smac mimetic | ||||
| GC37664 | Sorafenib (D3) | 1130115-44-4 | >99.00% | |
An internal standard for the quantification of sorafenib | ||||
| GC37665 | Sorafenib (D4) | 1207560-07-3 | - | |
Sorafenib D4 (Bay 43-9006 D4) 是 Sorafenib 氘代化合物标准品。Sorafenib 是一种多激酶抑制剂,抑制 Raf-1,B-Raf 和 VEGFR-3 的 IC50 分别为6 nM,20 nM,22 nM。 | ||||
| GC37668 | Soyasapogenol A | 508-01-0 | >99.00% | |
Soyasapogenol A是一种从Abrus cantoniensis根中分离得到的三萜类化合物,具有抗炎、抗癌、保肝和抗HIV-1等活性。 | ||||
| GC37669 | Soyasapogenol B | 595-15-3 | >98.00% / >99.50% | |
Soyasapogenol B是一种具有多种生物学活性的大豆成分。 | ||||
| GC37678 | SS28 | 141172-08-9 | - | |
SS28是具有口服生物利用度的SRT501 类似物,可抑制微管蛋白聚合,在G2/M引起细胞周期阻滞。SS28会引起细胞凋亡而不是坏死。 | ||||
| GC37688 | STAT3-IN-1 | 2059952-75-7 | >98.00% | |
STAT3-IN-1是一种强效、选择性且口服有效的STAT3抑制剂,在HT29和MDA-MB-231细胞中的IC 50 值分别为1.82μM和2.14μM。 | ||||
| GC37715 | Taccalonolide A | 108885-68-3 | - | |
Taccalonolide A 是一种微管稳定剂,是从 Tacca chantrieri 中分离得到的类固醇,具有细胞毒性和抗疟活性。Taccalonolide A 能引起 G2-M 期滞留、Bcl-2 磷酸化,并引发细胞凋亡。Taccalonolide A 在体外对过表达 p 糖蛋白 (Pgp)、多药耐药蛋白 7 (MRP7) 的细胞系具有显著的抑制作用,抑制SK-OV-3细胞生长的 IC50 值为 622 nM。 | ||||
| GC37745 | Taurodeoxycholic acid sodium hydrate | 110026-03-4 | >98.00% | |
Taurodeoxycholic acid sodium hydrate (Sodium taurodeoxycholate monohydrate), a bile acid, is an amphiphilic surfactant molecule synthesized from cholesterol in the liver. It activates S1PR2 pathway in addition to the TGR5 pathway. | ||||
